Koc-Kan Ho

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index732citations33works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(8), Cancer, Hypoxia, and Metabolism(7), Chemical Synthesis and Analysis(7), Receptor Mechanisms and Signaling(5), Click Chemistry and Applications(5)

Publications33 total

Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Supplementary Figures 1-4 from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Data from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Data from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Supplementary Figures 1-4 from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Eicosanoid regulation of debris-stimulated metastasis
Proceedings of the National Academy of Sciences·2021· 25 citedOpen Access
Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2)
Bioorganic & Medicinal Chemistry Letters·2013· 49 cited
Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
Molecular Cancer Therapeutics·2013· 69 cited
Synthesis and structure–activity relationship of 2-arylamino-4-aryl-pyrimidines as potent PAK1 inhibitors
Bioorganic & Medicinal Chemistry Letters·2013· 18 citedOpen Access
Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors
Bioorganic & Medicinal Chemistry Letters·2012· 29 citedOpen Access
Abstract 3762: Second generation PIM inhibitors exhibit improved activity in solid tumor models
Cancer Research·2012· 1 cited
Abstract 3226: PKM2 metabolic activator slows lung cancer xenograft growth
Cancer Research·2012
Epigenetic Drug Discovery: Targeting DNA Methyltransferases
SLAS DISCOVERY·2011· 156 citedOpen Access
Synthesis and SAR studies of novel 2-(6-aminomethylaryl-2-aryl-4-oxo-quinazolin-3(4H)-yl)acetamide Vasopressin V1b receptor antagonists
Bioorganic & Medicinal Chemistry Letters·2011· 7 citedOpen Access
Discovery of potent, soluble and orally active TRPV1 antagonists. Structure–activity relationships of a series of isoxazoles
Bioorganic & Medicinal Chemistry Letters·2011· 19 citedOpen Access
Structure–activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonists
Bioorganic & Medicinal Chemistry Letters·2010· 24 citedOpen Access
Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists
Bioorganic & Medicinal Chemistry Letters·2010· 7 citedOpen Access
Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist
Bioorganic & Medicinal Chemistry Letters·2010· 8 citedOpen Access
Discovery of novel quinolinone adenosine A2B antagonists
Bioorganic & Medicinal Chemistry Letters·2010· 12 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Jason M. Foulks(13), Michael V. McCullar(13), Steven B. Kanner(13), K. Mark Parnell(11), Maria L. Webb(11), Michael Ohlmeyer(11), Rebecca N. Nix(10), Adrianne Clifford(10), Anna V. Senina(9), Michael Saunders(8), Jeremy Bullough(8), Steven G. Kultgen(8), Jihua Liu(7), Virgil McCarthy(7), Marc O’Reilly(7), Bai Luo(7), Douglas S. Auld(6), David Vollmer(6), Yong Xu(6), Scott Pearce(6)